DKD. A. Kolodina

D. A. Kolodina

*This is an algorithmically generated author record based on publicly available information.

D. A. Kolodina has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of unfavorable prognosis in patients with coronary artery disease

    by D. A. Kolodina, O. D. Belyaeva, O. A. Berkovich, V. E. Larionova

    Предикторы неблагоприятного прогноза у больных ишемической болезнью сердца, перенесших коронарное шунтирование

  • Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coronary artery disease patients

    by Z.I. Ionova, O.A. Berkovich, O.D. Belyaeva, M.I. Zaraisky, D.A. Kolodina

    Background. Coronary artery disease (CAD) is determined by interaction of environmental factors with epigenetic and genetic factors. MicroRNA-21, microRNA-125a, microRNA-125b and microRNA-214 are small non-coding RNAs and the most important regulators of gene expression. MicroRNA-21, -125a, -125b and -214 are insufficiently studied in CAD patients. Objective. To explore serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in CAD patients with different features of clinical course. Material and methods. The study included 129 CAD patients (men 56.6% and women 43.4%) aged 63.17±8.57 years. The comparison group consisted of 45 people without CAD (men 55.6% and women 44.4%) aged 62.09±8.79 years (p>0.05). Serum microRNA expression was analyzed using real-time polymerase chain reaction. Relative microRNA expression was estimated in accordance with standard 2-ΔCt procedure. Results. Serum expression of microRNA-21, microRNA-125a, microRNA-125b and microRNA-214 is higher in CAD patients (p16.43 units increases the risk of CAD by 3.49 times (HR 3.49, 95% CI 1.70—7.17, p7.21 units — by 5.18 times (HR 5.18, 95% CI 2.29—11.69, p3.49 units — by 4.03 times (HR 4.03, 95% CI 1.86—8.72, p=0.0001), microRNA-214 expression >2.47 units — by 3.99 times (HR 3.99, 95% CI 1.91—8.37, p<0.001). Expression of microRNA-21 and microRNA-214 was higher in patients with early CAD than in older patients (p<0.05). Expression of microRNA-21, microRNA-125a, microRNA-125b and microRNA-214 was higher in CAD patients with myocardial infarction (MI) than in patients without MI (p<0.05). Conclusion. Expression of microRNA-21, microRNA-125a, microRNA-125b and microRNA-214 was higher in CAD patients than in the comparison group, as well as in CAD patients with MI. Expression of microRNA-21 and microRNA-214 was higher in patients with early CAD than in older patients.


  • Clinical observation of the patient with extra-articular manifestations of rheumatoid arthritis (rheumatoid nodules in the lungs)

    by O.D. Belyaeva, Russian Federation Saint Petersburg, D.A. Kolodina, E.A. Poygina, E.A. Bazhenova, N.A. Korelskaia

    Aim. Demonstration of clinical observation of a patient with a long-term history of rheumatoid arthritis with extra-articular manifestations (rheumatoid nodules in the lungs) and comorbid pathology. Key points. Rheumatoid nodules in the lungs are one of the rarest extraarticular manifestations of rheumatoid arthritis. Most often they are asymptomatic, and in most cases their specific treatment is not required. However, when they are detected, it is necessary to conduct a differential diagnosis to exclude a number of diseases (tuberculosis, neoplasia, etc.) and choose the right tactics for managing the patient. Conclusion. Differential diagnosis of lung lesions in patients with rheumatoid arthritis, including the differentiation of infectious (tuberculosis, etc.) and non-infectious (oncological diseases, etc.) processes, remains a difficult clinical task. It requires a comprehensive interdisciplinary approach: assessment of the risk of malignancy of the process, dynamic monitoring, consultations of various specialists. At the same time, a lung biopsy is not a routine diagnostic method. Keywords: rheumatoid arthritis, rheumatoid nodules, differential diagnosis, extraarticular manifestations.

  • Open Access

    Concentration omentin-1 in the serum of patients with coronary heart disease

    by A. S. Draganova, E. A. Polyakova, D. A. Kolodina, О. D. Belyaeva, О. A. Berkovich, T. L. Karonova, E. V. Shlyakhto

    Background. Omentin-1 (QM-1) — one of the most important anti-inflammatory adipocytokines produced by adipose tissue. It is known that its concentration is reduced in obese patients. However, the role of OM-\ in the pathogenesis of coronary heart disease (CHD), including acute coronary syndrome (ACS), is not fully determined.The objective of the study — to assess the level of OM-1 in blood serum of patients with ACS without ST-segment elevation (ACSWEST) who underwent percutaneous coronary intervention (PCI) and patients with stable CHD.Design and methods. Examined 104 patients with ACSWEST undergoing PCI. Comparison groups consisted of 38 patients without CHD according negative results of stress-echocardiography or coronary angiography, as well as 80 patients with stable CHD. All patients were evaluated anthropometric indicators: height, weight, waist circumference (WC), body mass index (BMI). Serum concentrations of OM-I were determined by enzyme immunoassay (DRG,USA), serum lipid profile was determined by enzymatic method.Results. In patients with ACSWEST who underwent PCI, the concentration of OM-I in the blood is lower than in those examined without atherosclerotic lesions of the coronary arteries [7.53 (5.00-10.55) ng/ml and 12.56 (7.84-15.34) ng/ml, respectively; p < 0.001). The concentration of OM-1 in the blood in patients with ACSWEST and a stable CHD did not differ (p > 0.05). In patients with ACSWEST, the concentration of OM-1 blood with multivascular lesions of the coronary arteries is lower than with 1-2 vascular lesions [7.30 (3.91- 8.17) ng/ml and 9.44 (6.54-9.93) ng/ml, respectively; p < 0.001. Similar patterns were established in patients with a stable CHD (p < 0.001).The concentration of OM-1 inthe blood in women with ACSWEST, with stable CHD and in those examined without CHD was higher than in men of the corresponding groups (p < 0.001).In patients with ACSWEST and with a stable CHD with overweight and obesity (WHO, 1999), the concentration of OM-1 inblood serum is lower than in patients with CHD and normal BMI (p < 0.001). In patients with ACSWEST and AO, the level of OM-1 inthe blood is lower than in patients with ACSWEST without AO, both in men and women (p < 0.001). When conducting a regression analysis, it was found that the concentration of OM-1 inthe blood of patients with ACSWEST is determined by BMI (b = -0.30, beta = -0.23, p = 0.002) and patient gender (b = 2.21, beta = 0.16, p = 0.029); in patients with a stable CHD — BMI (b = -0.38, beta = -0.27, p = 0.029).Conclusion. For patients with CHD, both with ACSWEST and with stable CHD, a low level of OM-1 in the blood is characteristic. The lowest OM-1 values were found in patients with multivascular coronary artery disease and obesity. The gender characteristics of the concentration of OM-1 in serum were established: the concentration of OM-1 in serum in women is higher than in men. A decrease in the concentration of OM-1 in the blood in patients with ACSWEST and with stable CHD is associated with BMI, the patient’s gender, and the severity of coronary atherosclerosis.


  • Open Access

    Expression of miRNA-27a in the serum of patients with non-ST elevation acute coronary syndrome who underwent percutaneous coronary intervention

    by A. S. Draganova, E. A. Polyakova, D. A. Kolodina, K. Yu. Mikheeva, O. D. Belyaeva, M. I. Zaraysky, O. A. Berkovich, Е. V. Shlyakhto, К. Ю. Михеева

    Экспрессия микроРНК-27а в сыворотке крови у пациентов с острым коронарным синдромом без подъема сегмента ST, перенесших чрескожное коронарное вмешательство